Stellar Biotechnologies, Inc. (OTCQB: SBOTF - TSX-V: KLH) is a world leader in development, manufacture and commercialization of keyhole limpet hemocyanin (KLH). KLH is an important biomedical material that is derived only from a limited natural source.
Stellar Biotechnologies is uniquely positioned: Leading KLH products and practices amid rising demand for KLH from biopharmaceutical companies, clinicians and immunology researchers.
Stellar Biotechnologies is the only company dedicated solely to developing and commercializing KLH. The company applies leading aquaculture technology and experience aimed at ensuring sustainable supply, together with proprietary manufacturing methods, to deliver a range of high quality KLH products.
Stellar Biotechnologies’ core business is production of purified KLH for use in a new class of medicines known as therapeutic vaccines and in immunological research. Stellar is also developing KLH-based assays for use in immunodiagnostic applications.
The recent rising demand for KLH is driven by pharmaceutical and biotechnology companies developing innovative therapies that target the immune system such as KLH-conjugated vaccines for a wide variety of serious chronic diseases, and those that utilize KLH for drug screening and to assess immune response in clinical and preclinical settings. Stellar Biotechnologies’ revenues are derived primarily from the sale of its KLH products and services to companies such as these, and from the award of federal grants such as from the National Institutes of Health and the National Science Foundation.